Founded with a mission to innovate noninvasive, topical treatments for corneal healing, Claris Biotherapeutics focuses on developing therapies for corneal wounds, ulcers, and scars. Their core product is a topical formulation that utilizes recombinant hepatocyte growth factor to accelerate the healing process. By addressing unmet needs in ophthalmology, Claris aims to provide healthcare providers with effective, noninvasive therapeutic options for sight-threatening corneal diseases.
Claris Biotherapeutics has garnered attention from notable investors and experts in the field of ophthalmology. The company has achieved significant milestones in preclinical and clinical trials, demonstrating the efficacy of their topical treatments. Their impact extends to improving the quality of life for millions affected by corneal diseases worldwide, positioning Claris as a leader in the field of corneal therapy.
